HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Chronic Lymphocytic Leukemia (CLL) is a type of cancer that begins in the blood-forming cells of the bone marrow and infiltrates the blood. It primarily affects a specific type of white blood cell called lymphocytes, which play a crucial role in the immune system. CLL is characterized by the gradual accumulation of abnormal lymphocytes, leading to overcrowding of the bone marrow and impairing its ability to produce healthy blood cells. These abnormal cells eventually spill into the bloodstream, circulating throughout the body. The exact cause of CLL is not well understood, but certain risk factors, such as age and family history, may increase the likelihood of developing this condition. CLL often progresses slowly, and many individuals may not experience noticeable symptoms in the early stages. When symptoms do occur, they may include fatigue, enlarged lymph nodes, weight loss, and frequent infections. While CLL is generally not curable, treatment options aim to manage symptoms, slow the progression of the disease, and improve the quality of life. Common treatment approaches include chemotherapy, immunotherapy, and targeted therapies. Regular monitoring and follow-up with healthcare professionals are essential for individuals with CLL to track the disease's progression and adjust treatment plans accordingly. Research continues to explore new therapeutic options and better understand the underlying mechanisms of CLL, offering hope for improved outcomes in the future.
